INSULET CORP PODD
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
4.78
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.7B | $247.1M | $1.9B | $377.7M | $1.5B |
| 2024 | $2.1B | $418.3M | $1.4B | $305.3M | $1.2B |
| 2023 | $1.7B | $206.3M | $1.2B | $70.1M | $732.7M |
| 2022 | $1.3B | $4.6M | $805.6M | -$3.9M | $476.4M |
| 2021 | $1.1B | $16.8M | $752.1M | -$180.0M | $556.3M |
| 2020 | $904.4M | $6.8M | $582.3M | -$45.0M | $603.6M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.78 (safe)
- Working capital / assets 0.387
- Retained earnings / assets 0.09
- EBIT / assets 0.149
- Equity / liabilities 0.904
Source: SEC EDGAR filings · CIK 0001145197 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.